Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01080664 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
A Phase 1 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
NCT01080664: Clinical Trial Phase 1 study, sponsored by EMD Serono.
NCT01080664 is a Phase 1 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 124 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01080664, a Phase 1 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
Study Summary
EMD Serono decided to terminate enrollment based on a review of the available clinical data and low probability of completing the trial based on the observed recruitment rate. Subjects already enrolled in the study continued participation in the study, consistent with the protocol, to study completion.
Primary Outcome
Dose-escalation part - The number of subjects experiencing at least a Dose-Limiting Toxicity (DLT), judged to be related to the study medication, evaluated over the first cycle only for each dose level and regimen, independently.
Interventions
- DRUG AS703569
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Why NCT01080664 stopped before completion
NCT01080664 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (107% higher).
The record links to 0 conditions, and to 1 intervention - of which AS703569 is the first listed.
NCT01080664 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01080664 about?
NCT01080664 is a clinical study titled "A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies". EMD Serono decided to terminate enrollment based on a review of the available clinical data and low probability of completing the trial based on the observed recruitment rate. Subjects already enrolled in the study continued participation in the study, consistent with the protocol, to study completi...
What is the current status of trial NCT01080664?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2006-12. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01080664?
The interventions under investigation include: AS703569 (DRUG).
Who is sponsoring clinical trial NCT01080664?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01080664's enrollment target sits among peer trials
124 471st of 2000 higher than 1,526 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia